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Purpose. A previous meta-analysis has conducted nonrandomized trials for mechanochemical ablation (MOCA). Since medium-
term follow-up data from randomized clinical trials (RCTs) are becoming available, we chose to perform a meta-analysis of
RCTs to assess the efficacy and safety of MOCA for saphenous vein insufficiency. Methods. A systematic search of all RCTs
comparing the anatomical success of MOCA for saphenous vein insufficiency to thermal ablation was performed using the
PubMed and Cochrane Library databases. We employed the Mantel-Haenszel random-effects meta-analysis of outcomes using
RevMan 5.3. Results. Four studies (615 patients) were included in this meta-analysis. The MOCA group had 93.4% and 84.5%,
whereas the thermal ablation group had 95.8% and 94.8% of anatomical success rate at 1 month (short-term) and a period of
more than 6 months but less than 1-year follow-up (mid-term), respectively. According to intention-to-treat analysis, there were
similar anatomical successes in MOCA and thermal ablation groups at the short-term follow-up (low-quality evidence; relative
risk ðRRÞ = 0:98 (95% CI, 0.94–1.03); P = 0:44; I2 = 53%). The estimated effect of MOCA on anatomical success showed a
statistically significant reduction at the mid-term follow-up (moderate-quality evidence; RR = 0:89 (95% CI, 0.84–0.95); P =
0:0002; I2 = 0%). MOCA had fewer incidence of nerve injury, deep vein thrombosis, and skin burns compared to the thermal
ablation procedure (low-quality evidence; RR = 0:33 (95% CI, 0.09–1.28); P = 0:11; I2 = 0%). Conclusion. MOCA offered fewer
major complications but lesser anatomical success at the period of more than 6 months but less than 1-year follow-up than
thermal ablation. Trial Registration. This trial is registered with UMIN Clinical Trial Registry (UMIN ID 000036727).
1. Introduction
Saphenous vein insufficiency is the most common chronic
venous incompetence of lower limbs. It affects more than
30% of adults [1]. The first-line treatment of venous incom-
petence is thermal ablation, e.g., radiofrequency ablation
(RFA) and endovenous laser ablation (EVLA) [2]. However,
the use of heat energy in thermal ablation was associated with
complications such as nerve injury and skin burns [3, 4].
To avoid thermal energy complications, few novel treat-
ments such as sclerotherapy, cyanoacrylate, and mechano-
chemical ablation (MOCA) have been introduced. One of
MOCA device is ClariVein (Merit Medical, South Jordan,
Utah) that combines mechanical injury to the venous endo-
thelium using a rotating wire with simultaneous delivery
and dispersion of a liquid sclerosant [5]. The liquid sclero-
sant causes irreversible damage to the cellular membranes
of the endothelium, resulting in the fibrosis of veins [6].
Another technique to produce a nontumescent sclerosant-
assisted ablation is by means of Flebogrif (Balton, Poland),
a device that is scratching the endothelium lining by a
dedicated catheter.
A previous meta-analysis has conducted nonrandomized
trials for MOCA [7]. It is important to study the use of
MOCA since medium-term follow-up data on randomized
clinical trials are now becoming available. Therefore, we
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performed a meta-analysis of randomized trials aiming to
assess the safety and efficacy of MOCA by comparing ther-
mal ablation for saphenous vein insufficiency.
2. Methods
All RCTs comparing the anatomical success of MOCA for
saphenous vein insufficiency (great saphenous vein (GSV),
small saphenous vein (SSV), or both) to the success rate of
a thermal ablation procedure were eligible for inclusion in
this review. All trials comparing MOCA to treatments other
than thermal ablation were excluded. A systematic search
of the literature was undertaken on July 7, 2019, after receiv-
ing an approval from the Institutional Review Board. Two
different databases (PubMed and Cochrane Library) were
used to perform a systematic search of all the literature with-
out language restriction. Search terms were differently
spelled text words or abbreviations, such as “varicose,”
“saphenous incompetence,” “saphenous insufficiency,”
“saphenous varicose veins,” “saphenous reflux,” “saphenous
vein,” “endovenous ablation,” “clarivein,” “MOCA,” “mecha-
nochemical ablation,” “randomized,” and “rct” in the title,
abstract, and medical subject heading (MeSH). Reference
lists of the included studies were also evaluated to identify
additional relevant studies. We followed the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
guidelines for research reporting.
Two investigators independently screened and assessed
titles and abstracts before full-text retrieval. The full papers
that potentially met the inclusion/exclusion criteria were
reviewed by the two authors for final inclusion. Subsequently,
two investigators extracted the data, which included authors,
year of publication, detailed intervention agent, veins treated
(either GSVs or SSVs), postprocedural management, number
of patients, primary outcomes, and adverse events. The
corresponding author was contacted to obtain any incom-
plete data. All extracted data were recorded with a dedicated
data extraction form on an Excel spreadsheet.
The primary outcome in our meta-analysis was anatom-
ical success that was defined either as complete occlusion of
the saphenous vein or at least proximal occlusion (>5 cm
proximally occluded with >5 cm distally open) on duplex
ultrasound (DUS) imaging. The primary outcome was
categorized at the short-term follow-up (1 month) and
mid-term follow-up (≥6 months but ≤1 year). Secondary
outcomes were phlebitis and major adverse event rates,
including nerve injury, DVT, and skin burns. Nerve injury
was reported differentially in the studies as sensory distur-
bance, paresthesia, or numbness. Other minor complications
(e.g., hematoma, lumps, and hyperpigmentation) were
excluded from the analysis.
Two authors independently assessed the methodological
quality of the articles using the Risk of Bias Tool (Cochrane
collaboration). They employed a GRADE approach to evalu-
ate the quality of evidence [8, 9]. Factors assessed for the risk
of bias were as follows [1]: randomization [2], adherence to
intervention [3], measurement [4], missing outcome data,
and reporting [5]. We evaluated the GRADE while taking
into account the following factors: risk of bias, imprecision,
indirectness of evidence, inconsistency in results among
included studies, and reporting bias.
We conducted the meta-analysis using relative risk (RR)
for anatomical success rates at short-term and mid-term
follow-up periods. We employed the Mantel−Haenszel
random-effects method using Review Manager (RevMan
v5.3 2014). We conducted an intention-to-treat (ITT)
analysis using imputation data according to event rates
among completers in the separate groups [10]. Available
case analysis was further performed as a sensitivity analysis.
We evaluated between and within-study heterogeneity using
the I2 statistic.
3. Results
A total of 100 studies were identified after our initial search
was completed (45 citations in PubMed and 55 in Cochrane
Library, as presented in Figure 1). Six studies were further
retrieved to review the full text. However, two studies were
excluded because one lacked a control and one was an in-
abstract study [11, 12]. Therefore, four studies were finally
included in our analysis [13–16]. Attempts to contact authors
to acquire unpublished data were uniformly unsuccessful. As
such, only information available from the publication was
used. Table 1 summarizes the clinical characteristics of the
included studies.
The Cochrane risk of bias analysis is shown in Figure 2.
There was a low risk of a randomization process in all
included trials. Blinding to participants and the delivering
clinicians was not performed in all included trials. There
was no placebo included for comparison. However, there
was assessor-blinding when evaluating the anatomical
success using DUS imaging. One trial was stopped early
because reimbursement of MOCA was suspended [13].
Participants who were not followed up ranged from 6% to
34%, and there were no documented reasons for loss to
follow-up. All trials reported the results from available case
analyses and not ITT analysis.
Table 2 shows the quality of evidence, and the GRADE
approach was used for each outcome. We did not downgrade
from the risk of bias aspect because most information was
from studies that were at low risk of bias. We downgraded
one level for the evidence of anatomical success at the
short-term follow-up because there was substantial heteroge-
neity. Indirectness did not appear to be an issue in all
outcomes. We downgraded the evidence of major complica-
tions for the imprecision aspect because there was a wide CI
that included no important effect and RR reduction greater
than 25%. The publication bias was assessed for all outcomes
because there was asymmetry from a visual inspection of the
funnel plot (Figure 3). This finding was not further evaluated
by conducting Egger’s test because there were less than 10
included trials.
The MOCA group had 93.4% of anatomical success
rate, whereas the thermal ablation group had 95.8% at the
1-month follow-up. According to the meta-analysis using
ITT as shown in Table 3, there were similar anatomical
successes in the MOCA and thermal ablation groups at
the 1-month follow-up (4 trials; RR = 0:98 (95% CI, 0.94–
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1.03); P = 0:44); however, there was substantial heterogene-
ity (I2 = 53%; P = 0:09). At the mid-term follow-up (≥6
months but ≤1 year), the MOCA group had 84.5% of
anatomical success rate, whereas the thermal ablation group
had 94.8% (Table 4). The estimated effect of MOCA on
anatomical success showed a statistically significant
reduction at the mid-term follow-up (3 trials; RR = 0:89
(95% CI, 0.84–0.95); P = 0:0002), without substantial
heterogeneity (I2 = 0%; P = 0:52).
We performed sensitivity analysis using the available case
analyses. The direction of effect did not change for anatomi-
cal success rates. MOCA did not decrease anatomical success
compared to thermal ablation at the 1-month follow-up (4
trials; RR = 0:98 (95% CI, 0.93–1.03); P = 0:46); however,
there was substantial heterogeneity (I2 = 56%; P = 0:08).
The RR for anatomical success at the mid-term follow-up
(≥6 months but ≤1 year) was significantly lower after treat-
ment with MOCA than that with thermal ablation (3 trials;
RR = 0:89 (95% CI, 0.84–0.96); P = 0:001), without substan-
tial heterogeneity (I2 = 0%; P = 0:67).
Table 5 shows the details of adverse events in the
four included trials. MOCA had fewer major complica-
tions compared to thermal ablation procedures (4 trials,
RR = 0:33 (95% CI, 0.09–1.28); P = 0:11; I2 = 0%). How-
ever, participants in the MOCA group had a higher risk
of phlebitis than the thermal ablation group (4 trials,
RR = 1:39 (95% CI, 0.67–2.86); P = 0:37; I2 = 0%).
4. Discussion
We report that MOCA had a similar anatomical success rate
with low-quality evidence at the 1-month follow-up, but
there was a reduction of the anatomical success rate with
moderate-quality evidence at the period of more than 6
months but less than 1-year follow-up compared with
thermal ablation. Previous meta-analyses that included
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Figure 1: PRISMA flow diagram.
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nonrandomized trials demonstrated that MOCA could be
considered an effective treatment for saphenous vein insuffi-
ciency; however, these results were based on a pooled analysis
of low-quality data [17]. In previous studies, the pooled ana-
tomical success rate at the mid-term follow-up was 91%,
97.1%, and 98.5% for MOCA, RFA, and EVLA, respectively
[7, 18]; the rates obtained in our study were lower: 84.5%
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Figure 2: Risk of bias assessment.
Table 2: GRADE assessment.
Comparison Outcomes Risk of bias Inconsistency Indirectness Imprecision Publication of bias GRADE
Anatomical success
Short-term No serious Some No at all No Presence Low
Mid-term No serious No No at all No Presence Moderate
Complication
Major complication No serious No No at all Some Presence Low
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Figure 3: Funnel plot of comparisons: mechanochemical ablation vs thermal ablation intention-to-treat analysis, outcome: anatomical
success short-term.
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assessor may have contributed to the lower anatomical
success rate observed in our study.
The major benefit of MOCA reported in previous
reviews was pain intensity reduction during the procedure
[17, 18]. However, we did not perform an analysis of pain
intensity because there was a high risk of measurement
bias from no participant blinding in the available trials.
The potential benefits in reducing the risk of nerve injury
might be of considerable clinical importance for MOCA.
Our meta-analysis indicated that MOCA had a lower risk
of major complications compared with thermal ablation.
Nerve injury was seen in 0.4% and 3.2% cases after
MOCA and thermal ablation, respectively.
There was disparity in terms of anatomical success
measure definitions, postprocedure management, and tech-
nical aspects of the MOCA procedure. Holejwin et al.
reported different results from the others as they used a
different sclerosant and categorized DUS image findings
into 3 categories instead of 4 [13]. The types of sclerosant
used by different studies may have influenced anatomical
success. There was substantial heterogeneity in anatomical
success at the short-term follow-up in our study. Removing
those trials improved the heterogeneity without changing
the direction of the effect. Therefore, the heterogeneity in
our study might be due to various types of sclerosants and
definitions of anatomical success.
There were a few limitations in our meta-analysis. First,
we evaluated efficacy only from the anatomical success rate
aspect, not from pain reduction, clinical success, or quality
of life aspects. Second, there was a wide CI around the effect
estimate of adverse event outcomes because there were few
events in this meta-analysis. Future trials are required. To
Table 3: Summary of findings.
Studies Participants Effect estimate Heterogeneity
ITT analysis
Anatomical success at short-term 4 615 RR 0.98 [0.94, 1.03]; P = 0:44 P = 0:09; I2 = 53%
Anatomical success at mid-term 3 496 RR 0.89 [0.84, 0.95]; P = 0:0002 P = 0:53; I2 = 0%
Available case analysis
Anatomical success at short-term 4 532 RR 0.98 [0.93, 1.03]; P = 0:46 P = 0:08; I2 = 56%
Anatomical success at mid-term 3 386 RR 0.89 [0.84, 0.96]; P = 0:001 P = 0:67; I2 = 0%
Adverse events
Major complication 4 615 RR 0.33 [0.09, 1.28]; P = 0:11 P = 0:73; I2 = 0%
Phlebitis 4 615 RR 1.39 [0.67, 2.86]; P = 0:37 P = 0:58; I2 = 0%
Table 4: Anatomical success and complication rates in each study.
Anatomical success rates DVT Sensory disturbances
Studies MOCA Thermal ablation MOCA Thermal ablation MOCA Thermal ablation
Short-term At the end of study At the end of study
Bootun et al. 2016 [15] 91.7% 91.5% 0% 1.7% 0% 0%
Holewijn et al. 2017 [13] 91.3% 99.0% 0% 0% 1.0% 2.9%
Lane et al. 2016 [16] 92.8% 91.5% 1.2% 1.2% 0% 0%
Vähäaho et al. 2019 [14] 100.0% 100.0% 0% 0% 0% 7.6%
Total 93.4% 95.8% 0.7% 1.4% 0.4% 3.2%
Mid-term
Lane et al. 2016 [16] 86.7% 92.7%
Vähäaho et al. 2019 [14] 86.4% 100.0%
Holewijn et al. 2017 [13] 81.6% 93.2%
Total 84.5% 94.8%
Table 5: Adverse events in the included trials.
Adverse events
Phlebitis DVT Nerve injury
MOCA Thermal ablation MOCA Thermal ablation MOCA Thermal ablation
Holewijn et al. 2017 [13] 12 8 0 0 1 3
Vähäaho et al. 2019 [14] 1 0 0 0 0 5
Bootun et al. 2016 [15] 0 2 0 1 Not reported Not reported
Lane et al. 2016 [16] 3 2 1 1 0 0
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date, there is one unpublished trial and one ongoing trial
investigating the anatomical success of MOCA compared
with thermal ablation [12, 19]. Lastly, the need of data atmore
than 1 year of outcome measurement at least is suggested.
5. Conclusion
Pooled analysis from limited trials demonstrated that MOCA
offered fewer major complications (DVT, nerve injury, and
skin burns) but lesser anatomical success at the period of
more than 6 months but less than 1-year follow-up than ther-
mal ablation. More RCTs together with proper homogeneous
data collection are needed to reach optimal information size.
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